Clinical Study

Spinal Cord Injury Trial (Sponsor: Mitsubishi)

Posted Date: Jun 14, 2021

  • Investigator: Justin Virojanapa
  • Specialties: Emergency Medicine, Neurology, Neurosurgery
  • Type of Study: Drug

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects with Acute Traumatic Cervical Spinal Cord Injury. This study investigates whether a study medication aimed at enhancing neurite growth could improve outcomes for patients with spinal cord injury. It involves 7 intravenous infusions over 5 months, with the first infusion to take place within 48 hours of the time of spinal cord injury. Each patient will be in the study for 9 months.


Potential Participants Will Have Sustained A Spinal Cord Injury Between C4 And C7 (Classified As Ais A, B, Or C) Within The Last 48 Hours. They Must Be Age 18-70, With A Body Mass Index <40 Kg/M2, And Able To Participate In The Study For 9 Months. Those With Injury Classified As Ais D Or E Are Not Eligible, Nor Are Patients With Complete Spinal Transection, Penetrating Spinal Cord Injury, Or Those Who Are Highly Anticipated To Be Dependent On Long-Term Mechanical Ventilation (E.G. Beyond 10-14 Days), Which Would Interfere With Study Procedures. Additional Eligibility Requirements Apply.


Spinal Cord Injury, Acute, Cervical

For More Information:

Karmen Herzig

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.